Acute lymphoblastic leukemia (ALL) continues to be the leading cause of childhood cancer, accounting for 25-30% of all diagnoses. Precursor B-cell leukemia, the most common type of childhood leukemia, occurs within a well-defined age period between 2 and 6 years of age. In contrast, infants o1 year of age develop a morphologically distinct leukemia with more aggressive features and a less favorable outcome, suggesting that certain undefined developmental factors may contribute to the variable development, presentation, and outcome of ALL. In addition, ALL demonstrates a novel ethnic variability in incidence with black, Caucasian, and Hispanic children at increasing comparative risk of developing ALL (15/million, 27/million, and 43/million, respectively). 1 Research has demonstrated a clear connection between development of ALL and certain rare genetic disorders such as Li-Fraumeni syndrome, but the vast majority of cases continue to have unclear genetic etiologies.
Since p53 protein serves to regulate the cell cycle, decreased p53 activity either through inherited mutation such as in Li-Fraumeni syndrome, acquired p53 mutations in neoplastic blast cells, or increased activity of p53-binding factor (MDM2) could lead to increased susceptibility to ALL. Prior research suggests that mutations in the p53 gene, although significant with respect to prognosis and treatment outcome, are relatively rare in childhood ALL.
2 Subsequent research has demonstrated that increased expression of MDM2 protein is associated with both worse prognosis and diminished treatment efficacy in childhood ALL. 3, 4 Work in cell culture by Bond et al 5 has demonstrated that the T309G polymorphism in the promoter region of MDM2 increases binding of transcription activator Sp1, resulting in increased production of MDM2 protein and subsequent attenuation of p53 function. Furthermore, this study demonstrated a distinct acceleration of sarcomas and breast cancers in patients diagnosed with Li-Fraumeni syndrome. However, the role of MDM2 T309G polymorphism on age of onset in leukemia, either sporadic or syndrome related, has not been previously studied.
In this study, we investigated the impact of MDM2 polymorphism status on the age of ALL disease onset in a cohort of Caucasian, black and Hispanic patients. Case samples were obtained via blood draw from 284 children diagnosed with B-lineage ALL between 1990 and 2005 at Children's Medical Center of Dallas. Approval from the University of Texas Southwestern Medical Center Institutional Review Board was attained and parents of each child signed consent to participate in genetic studies. The case samples were stratified into ethnicity-based cohorts with ethnic identity based on parental report (167 Caucasians, 81 Hispanics, 36 black patients). All identifiers other than age, sex, and ethnicity were stripped from the samples. All samples underwent standard DNA preparation procedures and were stored at 41C until genotyping was performed.
DNA samples from cases were arranged onto 96-well genotyping array plates with each well containing 3 ml genomic DNA (10 ng/ml). Genotyping was performed at the University of Texas Southwestern Medical Center McDermott Center for Human Growth and Development Core Facility, utilizing a TaqMAN/PCR-based nucleotide polymorphism discrimination test. In each well, 4 ml TaqMan Universal Master Mix (includes dNTPs, PCR buffer, and AmpliTaq Gold Polymerase), 1.6 pmol minorgroove binder (MGB) 6 labeled probe #1, 1.6 pmol MGB labeled probe #2, 10 pmol primer #1, 10 pmol primer #2 were Comparisons of age distribution for the homozygous cohorts and both the homozygous state (GG) cohort and the mixed heterozygous/homozygous (GG þ GT) cohorts were performed via Mann-Whitney rank sum testing, with a P-value of 0.05 considered statistically significant.
When comparisons were made between the ages of disease onset for the homozygous wild-type cohorts (TT) and the homozygous variant cohorts (GG) for both the aggregate cohort and the ethnic cohorts of Hispanics and Caucasians, no significant outcomes were discovered (P ¼ 0.0949, P ¼ 0.1389, and P ¼ 0.8026, respectively) ( Tables 2 and 3) . No P-value could be obtained for the black cohort since there was only one individual with a homozygous variant status in the study. The borderline significant outcomes in the aggregate and Caucasian cohorts suggest that the MDM2 polymorphism might have an ethnicity-specific effect on Caucasians, which subsequently influenced the aggregate cohorts. However, another theory might be that this effect is not ethnicity specific, but instead the low number of homozygous variant subjects in the Hispanic and black cohorts was inadequate to sufficiently power a significant outcome.
When the mean ages of onset were compared between homozygous wild type (TT) vs the presence of a variant allele (TG þ GG), several novel outcomes emerged. In the aggregate cohort, the mean age of disease onset for the homozygous wildtype cohort (85.227 months) vs that of the combined variant allele cohort (70.486 months) demonstrated a significant Table 3 Means with confidence intervals and non-parametric P-values for age of diagnosis (Figure 1 ). The incidence of p53 mutation in blast cells of childhood leukemia is low compared to other malignancies, and suggests a limited role in childhood leukemogenesis. However, modulation of p53 function via increased expression of MDM2 may be an alternate pathway to dysregulation of the cell cycle and/or the p53-related apoptotic pathway. Our study suggests that the T309G polymorphism for MDM2 significantly decreases the age of onset for ALL in the pediatric population, particularly within the Caucasian and black pediatric communities. However, our data does not support a relationship between MDM2 polymorphism status and age of onset for ALL within the Hispanic community. The explanation for this polymorphism's significant impact on Caucasian and black children, while not influencing disease development in Hispanic children remains unexplained. However, other studies investigating gene polymorphisms have demonstrated similar ethnicity-specific effects which might suggest interactions between gene polymorphisms and unidentified factors associated with ethnic status. 7, 8 Further research is needed to better elucidate these novel interactions and their impact on cancer susceptibility, prognosis, treatment efficacy, and age of onset. 
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